The Food and Drink, Veterinary Medicines and Residues (Amendment etc.) (EU Exit) Regulations 2019
| Jurisdiction | UK Non-devolved |
| Citation | SI 2019/865 |
| Year | 2019 |
(1) These Regulations may be cited as the Food and Drink, Veterinary Medicines and Residues (Amendment etc.) (EU Exit) Regulations 2019.(2) These Regulations come into force on the later of exit day or the day after the day on which they are made.(3) Regulation 17 and Schedule 8 extend to Great Britain.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . (1) Commission Delegated Regulation (EU) No 665/2014 supplementing Regulation (EU) No 1151/2012 of the European Parliament and of the Council with regard to conditions of use of the optional quality term ‘mountain product’ is amended as follows.(2) Omit Article 6(2) .(3) After Article 7 omit the words from “This Regulation” to “Member States.”.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . In Annex 2 to the EEA Agreement, in Chapter 27, omit points 8, 9, 9a, 9b and 9ba. The retained direct EU legislation listed in Schedule 7 is revoked. (1) The Veterinary Medicines Regulations 2013 (2) In regulation 4, after paragraph (3) insert—“ Application for a marketing authorisation for a pharmaceutical veterinary medicinal product ” ;in sub-paragraph (a) , for “a national application” substitute “ an application ” ;omit sub-paragraphs (b) and (c) ;in the heading, in the second column omit “national”;in the heading, in the third column omit “national”;for the heading for the fourth column (including the heading which straddles the fourth and fifth columns) substitute “Pharmacologically equivalent application”;omit the fifth and sixth columns;omit paragraph 8;for “a national application” substitute “ an application ” ;omit the words from “a decentralised” to “another member State”;in the heading, in the second column omit “National”;omit the third column;omit paragraph 10;for the heading substitute “ Application for a marketing authorisation based on informed consent ” ;for “fees” substitute “ fee ” ;for the text from “are in accordance” to the end (including the table) substitute “is £945 per application.”;in paragraph 15, for the table substitute the table in Part 2 of Schedule 8;omit paragraph 16;in the heading omit the words from “dealt with” to the end;omit the heading for the second column;omit the third and fourth columns;for sub-paragraph (2) substitute—“ £815 ” ;omit sub-paragraph (3) ;omit sub-paragraph (a) ;in sub-paragraph (b) , for “a third” substitute “ another ” .(1) Regulation (EC) No 470/2009 of the European Parliament and of the Council laying down Community
- (4) Schedule 1A (converted EU marketing authorisations) has effect.
- (2) The fees for a worksharing application are specified in the following table.
To continue reading
Request your trial